• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Eli Lilly and Company

    6/24/24 4:11:10 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    11-K 1 a2024form11-k.htm 11-K Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 11-K


    ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2023.
    OR
    o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
        For the transition period from __________________________to __________________________
    Commission file number 001-06351
    __________________________
    A.Full title of the plan and the address of the plan, if different from that of the issuer named below:

    The Lilly Employee 401(k) Plan
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    B.Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
    Eli Lilly and Company
    Lilly Corporate Center
    Indianapolis, Indiana 46285

    REQUIRED INFORMATION
    The following financial statements shall be furnished for the plan:
    1.Not applicable.
    2.Not applicable.
    3.Not applicable.
    4.The Lilly Employee 401(k) Plan and The Savings Plan for Lilly Affiliate Employees in Puerto Rico (the Plans) are subject to the requirements of the Employee Retirement Income Security Act of 1974 (ERISA). Attached hereto are copies of the most recent financial statements and schedule of the Plans prepared in accordance with the financial reporting requirements of ERISA.


    1


    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Financial Statements and Supplemental Schedules
    December 31, 2023 and 2022 and for the Year Ended December 31, 2023

    Table of Contents
    Report of Independent Registered Public Accounting Firm3
    Financial Statements
    Statements of Net Assets Available for Benefits - 20235
    Statements of Net Assets Available for Benefits - 20226
    Statements of Changes in Net Assets Available for Benefits7
    Notes to Financial Statements8
    Supplemental Schedules
    Schedule of Assets (Held at End of Year) -
         The Lilly Employee 401(k) Plan
    19
    Schedule of Assets (Held at End of Year) -
         The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    20
    Signatures21
    Exhibit 23 Consent of Independent Registered Public Accounting Firm23






    2


    Report of Independent Registered Public Accounting Firm


    To the Plan Participants and the Plan Administrator of The Lilly Employee 401(k) Plan and The Savings Plan for Lilly Affiliate Employees in Puerto Rico

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of The Lilly Employee 401(k) Plan and The Savings Plan for Lilly Affiliate Employees in Puerto Rico (the Plans) as of December 31, 2023 and 2022, and the related statements of changes in net assets available for benefits for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plans at December 31, 2023 and 2022, and the changes in their net assets available for benefits for the year ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

    Basis for Opinion

    These financial statements are the responsibility of the Plans’ management. Our responsibility is to express an opinion on the Plans’ financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plans in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plans are not required to have, nor were we engaged to perform, an audit of their internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plans’ internal control over financial reporting. Accordingly, we express no such opinion.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Schedules Required by ERISA

    The accompanying supplemental schedules of assets (held at end of year) as of December 31, 2023 (referred to as the “supplemental schedules”), have been subjected to audit procedures performed in conjunction with the audits of the Plans’ financial statements. The information in the supplemental schedules is the responsibility of the Plans’ management. Our audit procedures included determining whether the information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedules. In forming our opinion on the information, we evaluated whether such information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income
    3


    Security Act of 1974. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ Ernst & Young LLP

    We have served as the Plans’ auditor since at least 1990, but we are unable to determine the specific year.

    Indianapolis, Indiana

    June 24, 2024



    4


    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Statements of Net Assets Available for Benefits
    December 31, 2023
    The Savings
    Plan for Lilly
    Affiliate Employees in Puerto Rico
    The Lilly Employee
     401(k) Plan
    Assets
    Investments - Plan's interest in net assets of The Lilly Employee Savings Plan Master Trust: (Notes 3 and 4)
    Registered investment companies
    $336,555,962 $5,070,185 
    Self-directed brokerage accounts293,536,365 2,080,270 
    Eli Lilly and Company common stock2,666,987,306 173,154,575 
    Interest in common/collective trusts6,860,538,728 208,645,433 
    Synthetic GICs, at contract value932,994,905 50,131,737 
    Accrued income and pending trades - Sales3,340,013 141,546 
    Accrued expenses and pending trades - Purchases(4,926,436)(115,913)
    Plan's total interest in The Lilly Employee
    Savings Plan Master Trust
    11,089,026,843  439,107,833 
    Receivables:
    Employer contribution
    18,106,166 424,706 
    Notes receivable from participants26,081,722 2,338,156 
    Total Receivables44,187,888 2,762,862 
    Net Assets Available for Benefits$11,133,214,731 $441,870,695 
    See notes to financial statements.



    5


    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Statements of Net Assets Available for Benefits
    December 31, 2022
    The Savings
    Plan for Lilly
    Affiliate Employees in Puerto Rico
    The Lilly Employee
     401(k) Plan
    Assets
    Investments - Plan's interest in net assets of The Lilly Employee Savings Plan Master Trust: (Notes 3 and 4)
    Registered investment companies
    $298,728,521 $4,068,071 
    Self-directed brokerage accounts242,771,036 1,503,771 
    Eli Lilly and Company common stock1,758,747,132 108,941,431 
    Interest in common/collective trusts5,525,859,731 166,718,664 
    Synthetic GICs, at contract value1,012,590,902 52,177,045 
    Accrued income and pending trades - Sales1,146,291 20,240 
    Accrued expenses and pending trades - Purchases(1,533,745)(7,736)
    Plan's total interest in The Lilly Employee
    Savings Plan Master Trust
    8,838,309,868  333,421,486 
    Receivables:
    Employer contribution
    14,513,387 453,988 
    Notes receivable from participants22,432,099 1,990,660 
    Total Receivables36,945,486 2,444,648 
    Net Assets Available for Benefits$8,875,255,354 $335,866,134 
    See notes to financial statements.






    6


    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Statements of Changes in Net Assets Available for Benefits
    Year Ended December 31, 2023
    The Savings
    Plan for Lilly
    Affiliate Employees in Puerto Rico
    The Lilly Employee
    401(k) Plan
    Additions:
    Contributions:
    Participants$329,010,595 $8,996,979 
    Employer152,833,770 5,044,840 
    Total Contributions481,844,365 14,041,819 
    Interest in The Lilly Employee Savings Plan Master Trust investment income, net of administrative fees (Note 3)2,308,794,486 101,262,073 
    Interest income on notes receivable from participants1,363,495 122,234 
    Total Additions2,792,002,346 115,426,126 
    Deductions:
       Participant withdrawals557,399,435 9,193,811 
       Administrative expenses1,992,126 227,754 
    Total Deductions559,391,561 9,421,565 
    Net Increase Prior to Transfers2,232,610,785 106,004,561 
    Transfer from Other Plans25,348,592 — 
    Net Increase2,257,959,377 106,004,561 
    Net assets available for benefits at beginning of year8,875,255,354 335,866,134 
    Net assets available for benefits at end of year$11,133,214,731 $441,870,695 
    See notes to financial statements.

    7

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements
    December 31, 2023 and 2022
    Note 1 - Description of the Plans
    The accompanying financial statements comprise the employee savings plans of Eli Lilly and Company (the Company) and certain of the Company’s U.S. and Puerto Rico affiliates that participate in The Lilly Employee Savings Plan Master Trust (the Master Trust).
    General
    The Lilly Employee 401(k) Plan (the 401(k) Plan) was established for the benefit of eligible employees of Eli Lilly and Company and participating subsidiaries and affiliated companies. The Savings Plan for Lilly Affiliate Employees in Puerto Rico (the Puerto Rico Plan) was established for the benefit of resident eligible employees of, and certain employees within, the Commonwealth of Puerto Rico. The accompanying financial statements include the net assets and related activity of the 401(k) Plan and the Puerto Rico Plan.
    The following description of the 401(k) Plan and the Puerto Rico Plan (collectively, the Plans) provides only general information. Participants should refer to the applicable plan documents and the Plans’ summary plan descriptions for more complete information.
    The Northern Trust Company and Banco Popular de Puerto Rico are the trustees of the 401(k) Plan and the Puerto Rico Plan, respectively. Alight Solutions, LLC is the recordkeeper of the Plans. The Company is the plan sponsor for the 401(k) Plan, and Lilly del Caribe, Inc. is the plan sponsor for the Puerto Rico Plan. The Employee Benefits Committee of the Company is the plan administrator for the Plans.
    Full-time employees become eligible for participation in the Plans on the first day of employment. Seasonal, part-time, or other special-status employees must generally complete 1,000 hours of service within a 12-consecutive-month period to be eligible. The Plans allow for participant contributions from 1% to 50% of base compensation up to applicable regulatory limits. Participants have the option of enrolling in a program to increase their contribution rates automatically each year. Matching contributions by the Company are currently 100% of participant contributions up to the 6% participant contribution level, subject to applicable regulatory limits.
    Contributions
    Participants may designate that their contributions be invested in any of the investment options offered by the Plans. In addition, participants generally can buy and sell investments offered by the Plans, including the Eli Lilly and Company common stock fund (the Company Stock Fund), and transfer money from any of the investment options into and out of any of the other investment options. Company matching contributions are allocated based on a participant’s investment elections for their own contributions.

    8

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    The Company Stock Fund invests in the Company's common stock. The total return of the Company Stock Fund will reflect dividend payments to shareholders, as well as capital appreciation or depreciation. Except with respect to certain small dividend amounts, participants also are allowed to take payment of the Company Stock Fund dividends in cash in lieu of having them reinvested in their participant accounts. The Company Stock Fund holds a small percent of assets in cash equivalents for liquidity purposes. Therefore, the Company Stock Fund may not reflect the exact performance of the underlying security over any given time period.
    Vesting
    All participants are vested immediately in their own contributions. Effective January 1, 2023, all active participants vest in 100% of the Company's matching contributions after completing one hour of creditable service.
    Participant Loans
    Participants may borrow from their accounts a minimum of $1,000 and a maximum of the least of (1) one-half of the amount of the participant’s vested account, (2) 90% of the portion of the participant’s account balance attributable to the participant’s pretax contributions and rollover account, and (3) $50,000 (all of which are reduced by any unpaid loan balance). The loans are collateralized by the participant’s vested account and bear interest at prime plus 1%. Should the participant terminate as an employee, the balance of the outstanding loan becomes due and payable.
    Payment of Benefits
    Participants may elect to receive distributions upon termination in the form of one or more lump-sum payments or various installment annuities. Participants may also be eligible to take voluntary, in-service withdrawals, including hardship withdrawals, non-hardship withdrawals, and age 59 ½ withdrawals. Mandatory distributions are made in accordance with the Plans' provisions.
    Termination
    The Plans are subject to and are intended to comply with the provisions of the Employee Retirement Income Security Act of 1974 (ERISA), as amended, and applicable IRS and Puerto Rico Treasury requirements. The Company has the right to terminate the Plans subject to the provisions of ERISA and the Plans, as established in the applicable plan documents. In the event the Plans are terminated, each
    9

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    participant’s account shall be nonforfeitable with respect to both the employee’s and the Company’s contributions, and the net assets are to be set aside for payment of withdrawals by participants.
    Administrative Expenses
    The Plans' administrative expenses are paid for either by the Plans or by the Plans' sponsors. Administrative expenses that are paid directly by the Plans' sponsors are excluded from these financial statements. Participants are charged a percentage of their account balances to pay administrative expenses. Participants are assessed separate fees for certain transactions including, but not limited to, loans, maintaining a self-directed brokerage account, and/or processing of a qualified domestic relations order, as applicable.
    Note 2 - Significant Accounting Policies.
    Investment Valuation and Income Recognition

    Investments held by the Master Trust are stated at fair value, except for fully benefit-responsive synthetic guaranteed investment contracts (synthetic GICs), as noted below. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). See Note 4 for further discussion of fair value measurements.
    The Master Trust invests in fully benefit-responsive synthetic GICs, which are stated at contract value. Contract value represents contributions made under each contract, plus earnings, less participant withdrawals and administrative expenses. Contract value is the relevant measure for fully benefit-responsive investment contracts because this is the amount received by participants if they were to initiate permitted transactions under the terms of the Plans.

    Notes Receivable from Participants
    Notes receivable from participants represent participant loans that are recorded at their unpaid principal balances plus any accrued but unpaid interest. Interest income on notes receivable from participants is recorded when it is earned. No allowance for credit losses has been recorded as of December 31, 2023 and 2022. If a participant ceases to make loan repayments and the plan administrator deems the participant loan to be a distribution, the participant loan balance is reduced, and a benefit payment is recorded.
    Use of Estimates and Basis of Accounting
    The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates that affect the amounts reported in the financial statements and accompanying notes and supplemental schedules. Actual results could differ from these estimates. The accompanying financial statements have been prepared on the accrual basis of accounting.
    10

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    Note 3 - Master Trust
    The Plans provide that both participant contributions and company matching contributions be held in a trust by an independent trustee for the benefit of participating employees. As of December 31, 2023 and 2022, The Northern Trust Company maintained the accounting of the aggregate value of assets associated with each Plan participating in the Master Trust. The Plans have specific interests in certain investments of the Master Trust based on account balances of the participants and their investment options. The Master Trust assets are allocated among the participating plans by assigning to each plan those transactions (primarily contributions, benefit payments, and plan-specific expenses) that can be specifically identified for such plan or participants in such plan and by allocating among all plans, in proportion to the fair value of the assets attributable to each participating plan, the income (loss), including net appreciation/depreciation in fair value of investments, and expenses resulting from the collective investment of the assets of the Master Trust.
    Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded as earned. Dividends are recorded on the ex-dividend date. Net appreciation/depreciation includes gains and losses on investments bought and sold, as well as held during the year.
    Net investment income for the Master Trust for the year ended December 31, 2023 is as follows:
    Net realized and unrealized gains on investments$2,356,863,418 
    Interest income, net of expenses22,227,766 
    Dividend income30,965,375 
    Net investment income$2,410,056,559 

    The interests in the net assets of the Master Trust of the 401(k) Plan and the Puerto Rico Plan are presented in the accompanying financial statements.
    The Plans (through the Master Trust) hold synthetic GICs with third-party financial service institutions. The synthetic GICs are wrap contracts paired with an underlying investment portfolio of common/collective trust funds that invest in average-quality, short/intermediate-term, fixed-income securities. A synthetic GIC credits the holder’s account with a stated crediting rate for a specified period of time. Investment gains and losses are amortized over the expected duration through the calculation of the crediting rate applicable to the Plans on a prospective basis. Synthetic GICs provide for a variable crediting rate, which typically resets at least quarterly, and the issuers of the wrap contract provide a guarantee that future adjustments to the crediting rate cannot result in a crediting rate less than zero.
    The crediting rate is primarily based on the current yield-to-maturity of the covered investments, plus or minus amortization of the difference between the market value and contract value of the covered investments over the expected duration at the time of computation. The crediting rate is impacted by the
    11

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    change in the annual effective yield-to-maturity of the underlying securities but is also affected by the differential between the contract value and the market value of the covered investments.
    Generally, contract value withdrawals will be made pro rata based on the percentage of investments covered by each issuer. The terms of the wrap contracts generally provide for full contract value withdrawal only upon termination of the contract or total liquidation of the covered investments. Contract termination occurs whenever the contract value or market value of the covered investments reaches zero or upon certain events of default. If the contract terminates due to issuer default (other than a default occurring because of a decline in its rating), the issuer will generally be required to pay to the Plans the excess, if any, of contract value over market value on the date of termination. If the contract terminates when the market value equals zero, the issuer will pay the excess of contract value over market value to the Plans to the extent necessary for the Plans to satisfy outstanding contract value withdrawal requests. Contract termination also may occur by either party upon election and notice. However, such election by a contract issuer typically allows for a gradual asset risk wind-down generally over the portfolio’s duration and would maintain contract value on the Plans.
    Certain events, including (1) certain amendments to the Plans' documents (including complete or partial plan termination or merger with another plan), (2) changes to the Plans’ prohibition on competing investment options or deletion of equity wash provisions, (3) bankruptcy of the Plans' sponsors or other Plans' sponsor events that cause a significant withdrawal from the Plans, and (4) the failure of the Master Trust to qualify for exemption from federal income taxes or any required prohibited transaction exemption under ERISA, limit the ability of the Plans to transact contract value withdrawals from the wrap contracts. The plan administrator believes that the occurrence of any such event which would limit the Plans’ ability to transact contract value withdrawals is not probable of occurring.
    The synthetic GICs generally impose conditions on both the Plans and the issuer. If an event of default, as defined, occurs and is not cured, and the Plans are unable to negotiate continuing coverage or obtain a replacement investment contract, the Plans may experience losses if the value of the Plans’ assets no longer covered by the contract is below contract value. The combination of the default of an issuer and an inability to obtain replacement coverage could render the Plans unable to achieve their objective of maintaining a stable contract value. The plan administrator does not believe the occurrence of any such event has occurred or is probable of occurring.
    12

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    Note 4 - Fair Value Measurements
    Accounting Standards Codification (ASC) 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC 820 includes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described below:
    Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.
    Level 2 - Inputs to the valuation methodology include:
    •Quoted prices for similar assets and liabilities in active markets
    •Quoted prices for identical or similar assets or liabilities in markets that are not active
    •Inputs other than quoted prices that are for the assets or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals)
    •Inputs that are derived principally from or corroborated by observable market data by correlation or other means
    If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
    Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
    The level in the fair value hierarchy within which the fair value measurement is classified is determined based upon the lowest level of input that is significant to the fair value measurement in its entirety.
    The following is a description of the valuation techniques and inputs used for assets measured at fair value:
    •Registered investment companies (mutual funds) - Valued at the net asset value (NAV) of shares held by the Master Trust at year end, as quoted in the active market, and are classified within Level 1 of the valuation hierarchy.
    13

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    •Self-directed brokerage accounts (represents mutual funds and exchange-traded funds) - Valued at the NAV of shares held by the Master Trust at year end, as quoted in the active market, and are classified within Level 1 of the valuation hierarchy.
    •Eli Lilly and Company common stock - Valued at the closing price reported on the New York Stock Exchange and are classified within Level 1 of the valuation hierarchy.
    •Interest in common/collective trusts - Represents interests in pooled investment vehicles designed primarily for collective investment of employee benefit trusts. The fair value of the investments in this category has been estimated using the NAV per unit as a practical expedient provided by the fund managers. Redemption restrictions range from 1 to 30 days, and there were no unfunded commitments in this investment category.
    The valuation methodologies described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plans believe their valuation methods are appropriate and consistent with those of other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. There have been no changes in the methodologies used at December 31, 2023 and 2022.
    The following table sets forth the net assets of the Master Trust and the Master Trust's assets carried at fair value as of December 31, 2023, by level, within the fair value hierarchy:
    Master Trust
    BalanceLevel 1Level 2Level 3
    Investments at fair value:
       Registered investment companies$341,626,147 $341,626,147 $— $— 
       Self-directed brokerage accounts295,616,635 295,616,635 — — 
       Eli Lilly and Company common stock2,840,141,881 2,840,141,881 — — 
            Total3,477,384,663 $3,477,384,663 $— $— 
    Interest in common/collective trusts, measured at NAV
    7,069,184,161 
            Total Master Trust investments
               at fair value
    10,546,568,824 
    Investments at contract value –
       Synthetic GICs
    983,126,642 
            Total Master Trust investments$11,529,695,466 

    14

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    The following table sets forth the net assets of the Master Trust and the Master Trust's assets carried at fair value as of December 31, 2022, by level, within the fair value hierarchy:

    Master Trust
    BalanceLevel 1Level 2Level 3
    Investments at fair value:
       Registered investment companies$302,796,592 $302,796,592 $— $— 
       Self-directed brokerage accounts244,274,807 244,274,807 — — 
       Eli Lilly and Company common stock1,867,688,563 1,867,688,563 — — 
            Total2,414,759,962 $2,414,759,962 $— $— 
    Interest in common/collective trusts, measured at NAV
    5,692,578,395 
            Total Master Trust investments
               at fair value
    8,107,338,357 
    Investments at contract value –
       Synthetic GICs
    1,064,767,947 
            Total Master Trust investments$9,172,106,304 
    Note 5 - Income Tax Status
    The 401(k) Plan has received a determination letter from the IRS dated June 13, 2017, confirming generally that the 401(k) Plan meets the qualification requirements under Section 401(a) of the Internal Revenue Code (the Code) and, therefore, the related trust is exempt from taxation. Subsequent to the effective date of the determination letter, the 401(k) Plan was amended. Once qualified, the 401(k) Plan is required to operate in conformity with the Code to maintain its qualification. The plan administrator believes that the 401(k) Plan is being operated in compliance with applicable requirements of the Code and, therefore, believes that the 401(k) Plan remains qualified and the related trust is tax exempt.
    The Puerto Rico Plan received a determination letter from the Commonwealth of Puerto Rico’s Department of Treasury dated July 19, 2021, confirming generally that the Puerto Rico Plan meets the qualification requirements of Section 1081.01 of the Puerto Rico Internal Revenue Code of 2011 (the Puerto Rico Code). Subsequent to the effective date of the determination letter, the Puerto Rico Plan was amended. Once qualified, the Puerto Rico Plan is required to operate in conformity with the Puerto Rico Code to maintain its qualification. The plan administrator believes that the Puerto Rico Plan is being operated in compliance with applicable requirements of the Puerto Rico Code and, therefore, believes that the Puerto Rico Plan is qualified and the related trust is tax exempt.
    Accounting principles generally accepted in the United States require plan management to evaluate tax positions taken by the Plans and recognize a tax liability if the Plans have taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. Plan management has analyzed the tax positions taken by the Plans and has concluded that there are no uncertain positions taken or
    15

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    expected to be taken. The Plans are subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.
    Note 6 - Risks and Uncertainties
    The Plans invest in various investment securities. Investment securities are exposed to various risks, such as interest rate, credit, and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the statements of net assets available for benefits.
    Note 7 - Transactions with Related Parties
    The Plans invest in the common stock of the Company. During 2023, the 401(k) Plan received approximately $21,404,000 in cash dividends from the Company on the common stock of the Company owned by the 401(k) Plan. During 2023, the Puerto Rico Plan received approximately $1,336,000 in cash dividends from the Company on the common stock of the Company owned by the Puerto Rico Plan. Certain plan assets are in investments managed by The Northern Trust Company. These transactions qualify as party-in interest transactions; however, they are exempt from the prohibited transaction rules under ERISA and applicable regulatory guidance.
    16

    The Lilly Employee 401(k) Plan and
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Notes to Financial Statements, cont.
    December 31, 2023 and 2022

    Note 8 - Reconciliation of the Financial Statements to Form 5500
    The following are reconciliations of net assets available for benefits as of December 31, 2023 and 2022, and the net increase in net assets available for benefits for the year ended December 31, 2023, with the corresponding amounts in the Form 5500:
    December 31, 2023
    401(k) PlanPuerto Rico Plan
    Net assets available for benefits at year end, as reported in the
       accompanying financial statements$11,133,214,731 $441,870,695 
    Distributions accrued on Form 5500 at year end(2,765,739)(3,943)
    Net assets available for benefits per Form 5500$11,130,448,992 $441,866,752 
    December 31, 2022
    401(k) PlanPuerto Rico Plan
    Net assets available for benefits at year end, as reported in the
       accompanying financial statements$8,875,255,354 $335,866,134 
    Distributions accrued on Form 5500 at year end(2,190,315)(116,992)
    Net assets available for benefits per Form 5500$8,873,065,039 $335,749,142 

    Year Ended December 31, 2023
    401(k) PlanPuerto Rico Plan
    Net increase in net assets available for benefits, as
    reported in the accompanying financial statements
    $2,257,959,377 $106,004,561 
    Distributions accrued on Form 5500 at December 31, 2023(2,765,739)(3,943)
    Distributions accrued on Form 5500 at December 31, 20222,190,315 116,992 
    Net increase in net assets available for benefits, as
    reported on the Form 5500
    $2,257,383,953 $106,117,610 



    17



















    Supplemental Schedules














    18


    The Lilly Employee 401(k) Plan
    EIN 35-0470950 Plan No. 002
    Schedule H, Line 4i – Schedule of Assets
    (Held at End of Year)
    December 31, 2023
     
     
    Description of
    Investment, including
    Maturity Date, Rate of
    Identity of Issuer, Borrower,Interest, Par, orCurrent
    Lessor, or Similar PartyMaturity ValueValue
    Loans to participants*Interest rates ranging$26,081,722 
       from 4.25% to 10.25%
    *Parties in interest

    19






    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    EIN 98-0167031 Plan No. 004
    Schedule H, Line 4i – Schedule of Assets
    (Held at End of Year)
    December 31, 2023
    Description of
    Investment, including
    Maturity Date, Rate of
    Identity of Issuer, Borrower,Interest, Par, orCurrent
    Lessor, or Similar PartyMaturity ValueValue
    Loans to participants*Interest rates ranging$2,338,156 
       from 4.25% to 9.50%
    *Parties in interest



















    20


    SIGNATURES

    The Plans. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the Plans) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

        
    The Lilly Employee 401(k) Plan
    Date: June 24, 2024
    By: /s/ Stacey M. Roberson
          Stacey M. Roberson
    Employee Benefits Committee Member
    The Savings Plan for Lilly Affiliate Employees in Puerto Rico
    Date: June 24, 2024
    By: /s/ Stacey M. Roberson
    Stacey M. Roberson
    Employee Benefits Committee Member
    21


    Exhibit Index

    Exhibit
    Number        Description

    23            Consent of Independent Registered Public Accounting Firm





    22


    Exhibit 23

    Consent of Independent Registered Public Accounting Firm
    We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-172422 and 333-258801) pertaining to The Lilly Employee 401(k) Plan and The Savings Plan for Lilly Affiliate Employees in Puerto Rico of Eli Lilly and Company of our report dated June 24, 2024, with respect to the financial statements and schedules of The Lilly Employee 401(k) Plan and The Savings Plan for Lilly Affiliate Employees in Puerto Rico included in this Annual Report (Form 11-K) for the year ended December 31, 2023.


    /s/ Ernst & Young LLP
    Indianapolis, Indiana
    June 24, 2024

    23
    Get the next $LLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    1/7/2026$1250.00Buy
    UBS
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    10/20/2025$840.00 → $930.00Outperform
    BMO Capital Markets
    10/14/2025Hold → Buy
    Erste Group
    More analyst ratings

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

    12/16/25 8:49:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman reiterated coverage on Eli Lilly with a new price target

    Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

    12/15/25 10:37:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    SEC Filings

    View All

    SEC Form 10-K filed by Eli Lilly and Company

    10-K - ELI LILLY & Co (0000059478) (Filer)

    2/12/26 1:58:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    2/4/26 7:05:22 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    11/21/25 4:19:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance, & CAO Zakrowski Donald A was granted 584 shares, increasing direct ownership by 21% to 3,423 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:27:28 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya was granted 4,163 shares, increasing direct ownership by 15% to 32,304 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:26:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Pres LLY Oncology&HdCorpBD Van Naarden Jacob was granted 4,866 shares, increasing direct ownership by 22% to 26,626 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:25:13 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly declares first-quarter 2026 dividend

    INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov

    12/8/25 2:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care